OncoMatch/Clinical Trials/NCT03829540
CD4CAR for CD4+ Leukemia and Lymphoma
Is NCT03829540 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies CD4CAR for t-cell lymphoma.
Treatment: CD4CAR — This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells. Funding Source - FDA OOPD
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD4 overexpression (CD4+)
CD4+ T cell hematologic malignancies
Demographics
Prior therapy
Cannot have received: investigational cell/gene therapy
Cannot have received: investigational anticancer agent
Lab requirements
Kidney function
Creatinine clearance of > 60 ml/min (or otherwise non clinically-significant, per study investigator)
Liver function
ALT/AST < 3 x ULN; Bilirubin < 2 x ULN
Cardiac function
Adequate cardiac function with EF of ≥50%
Creatinine clearance of > 60 ml/min (or otherwise non clinically-significant, per study investigator); ALT/AST < 3 x ULN; Bilirubin < 2 x ULN; Adequate cardiac function with EF of ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami Sylvester Comprehensive Cancer Center · Miami, Florida
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center · Indianapolis, Indiana
- Riley Hospital for Children · Indianapolis, Indiana
- Albert Einstein Health Network · New York, New York
- Stony Brook Cancer Center · Stony Brook, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03829540 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational cell/gene therapy, investigational anticancer agent disqualifies patients from enrollment.
Does this trial require CD4?
Yes, CD4 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify